Christine Dr Christine Galustian Academics Group leader (non-clinical) Prostate Cancer Immunotherapy group Senior Fellow. Contact details christine.galustian@kcl.ac.uk +44 (0) 2071881910
Editorial: Immunotherapy for Prostate Cancer – turning the immunological desert into an oasis of hope Galustian, C., Dalgleish, A., Bodman-Smith, M., Kusmartsev, S. & Dasgupta, P., 8 Sep 2022, In: Frontiers in oncology. 12, 1021870. Research output: Contribution to journal › Editorial › peer-review. DOIs: https://doi.org/10.3389/fonc.2022.1021870 Cytotopic (Cyto-) IL-15 as a New Immunotherapy for Prostate Cancer: Recombinant Production in Escherichia coli and Purification Esteves, A. M., Papaevangelou, E., Smolarek, D., Dasgupta, P. & Galustian, C., 27 Oct 2021, In: Frontiers in Molecular Biosciences. 8, 755764. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.3389/fmolb.2021.755764 IL-15 upregulates telomerase expression and potently increases proliferative capacity of NK, NKT-like, and CD8 T cells Watkinson, F., Nayar, S., Rani, A., Sakellariou, C., Elhage, O., Papaevangelou, E., Dasgupta, P. & Galustian, C., 18 Jan 2021, In: Frontiers in Immunology. 11, p. 594620 1 p., 594620. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.3389/fimmu.2020.594620 Combination of Interleukin-15 with a STING agonist, ADU-S100 analog: a potential immunotherapy for prostate cancer Da Silva Esteves, A. M., Papaevangelou, E., Dasgupta, P. & Galustian, C., 12 Jan 2021, (Accepted/In press) In: Frontiers in oncology. Research output: Contribution to journal › Article › peer-review Targeting prostate cancer using intratumoral cytotopically-modified interleukin-15 immunotherapy in a syngeneic murine model Papaevangelou, E., Smolarek, D., Smith, R., Dasgupta, P. & Galustian, C., 27 Jul 2020, In: Immunotargets and therapy. 2020, 9, p. 115—130 Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.2147/ITT.S257443 Prostate cancer cells enhance interleukin-15-mediated expansion of NK cells Sakellariou, C., Elhage, O., Papaevangelou, E., Giustarini, G., Da Silva Esteves, A. M. E., Smolarek, D., Smith, R., Dasgupta, P. & Galustian, C., 7 Aug 2019, In: BJU International. 125, 1, p. 89-102 14 p. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.1111/bju.14893 Mutation of duffy antigen receptor for chemokines (DARC) as an indicator of prostate cancer severity in Afro-Caribbean men Galustian, C., Rani, A., Cahill, F., Santaolalla, A., Gillett, C., Lombardelli, C., Rosekilly, J., Sakellariou, C., George, G., Papaevangelou, E., Smith, R., Smolarek, D., Van Hemelrijck, M. & Dasgupta, P., 24 Mar 2017, In: EUROPEAN UROLOGY SUPPLEMENTS. 16, 3, p. e622-e623 Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.1016/s1569-9056(17)30419-0 REGULATION OF THE CCL2-CCR2 AXIS THROUGH THE JAK-STAT PATHWAY AND ROLE IN CANCER METASTASIS Rani, A., Murphy, J. & Galustian, C., Nov 2016, In: Cytokine. 87, p. 59-+ Research output: Contribution to journal › Article › peer-review Immune checkpoint blockade – a treatment for urological cancers? Elhage, O., Galustian, C. & Dasgupta, P., Oct 2016, In: BJU International. 118, 4, p. 498-500 3 p. Research output: Contribution to journal › Comment/debate › peer-review. DOIs: https://doi.org/10.1111/bju.13571 Cathepsin-L and Transglutaminase Dependent Processing of ps20: A novel Mechanism for ps20 Regulation via ECM Cross-Linking Hickman, O. J., Dasgupta, P., Galustian, C., Smith, R. A. & Vyakarnam, A., Sep 2016, In: Biochemistry and Biophysics Reports . 7, p. 328–337 10 p. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.1016/j.bbrep.2016.06.010 View all publications